What is the recommended dosing, monitoring, and contraindications for NUBEQA (darolutamide) in patients with non‑metastatic castration‑resistant prostate cancer receiving continuous androgen‑deprivation therapy?

NUBEQA (Darolutamide) for Non-Metastatic Castration-Resistant Prostate Cancer

For patients with non-metastatic castration-resistant prostate cancer (nmCRPC) at high risk for developing metastatic disease, NUBEQA (darolutamide) 600 mg (two 300 mg tablets) should be administered orally twice daily with food, while continuing androgen deprivation therapy (ADT) to maintain castrate testosterone levels (<50 ng/dL). 1

Recommended Dosing

• Standard dose: 600 mg (two 300 mg tablets) orally twice daily
• Administration: Take with food; swallow tablets whole 1
• Continue concurrent ADT: Maintain with GnRH analog or following bilateral orchiectomy 1

Dose Modifications for Specific Populations

• Severe renal impairment (not on hemodialysis): Reduce to 300 mg twice daily 1
• Moderate hepatic impairment: Reduce to 300 mg twice daily 1
• Mild renal or hepatic impairment: No dose adjustment needed

Patient Selection Criteria

NUBEQA is indicated specifically for nmCRPC patients at high risk for metastatic progression, defined as:

• Rising PSA >2 ng/mL above nadir
• PSA rise ≥25% over nadir, confirmed by second PSA ≥3 weeks later
• Castrate testosterone levels (<50 ng/dL)
• PSA doubling time ≤10 months (key high-risk criterion) 2, 3
• No radiographic evidence of metastatic disease on conventional imaging

The AUA guideline emphasizes that patients with PSA doubling time >10 months have relatively indolent disease and can consider monitoring with continued ADT alone 2.

Monitoring Requirements

Baseline Assessment

• Confirm castrate testosterone level (<50 ng/dL) 2
• Radiographic imaging to exclude metastatic disease
• Thyroid function testing (TSH) - particularly important given darolutamide's association with hypothyroidism 2
• Cardiovascular risk assessment 1

Ongoing Monitoring

• Radiographic imaging every 16 weeks to assess for metastasis 3
• PSA monitoring regularly
• TSH monitoring - hypothyroidism occurred in 8.1% vs 2.0% with placebo; events were grade 1-2 and identified early 2, 1
• Cardiovascular monitoring for ischemic heart disease (4% incidence) and heart failure (2.1% incidence) 1
• Liver function tests (AST increased in 23% vs 14% placebo; bilirubin increased in 16% vs 9%) 1
• Complete blood count (neutropenia in 20% vs 9% placebo) 1

Contraindications and Precautions

Absolute Contraindications

None listed in FDA labeling 1

Warnings and Precautions

Ischemic Heart Disease 1:

• Optimize cardiovascular risk factors before initiating therapy
• Monitor for signs/symptoms of coronary artery disease
• Discontinue for Grade 3-4 cardiac events
• Ischemic heart disease occurred in 4% of patients

Seizure Risk 1:

• Consider discontinuation if seizure develops during treatment
• Notably, darolutamide showed no increased seizure risk compared to placebo in ARAMIS trial (0.2% vs 0%), contrasting favorably with other androgen receptor inhibitors 2, 3

Embryo-Fetal Toxicity 1:

• Males with female partners of reproductive potential must use effective contraception during treatment and for 1 week after final dose

Common Adverse Events

Most Frequent (>2% with ≥2% increase over placebo) 1:

• Fatigue: 16% (vs 11% placebo) - most common symptomatic adverse event
• AST increased: 23% (vs 14% placebo)
• Neutrophil count decreased: 20% (vs 9% placebo); Grade 3-4 in 4%
• Bilirubin increased: 16% (vs 9% placebo)
• Pain in extremity: 6% (vs 3% placebo)
• Rash: 4% (vs 1.4% placebo)

Discontinuation Rates

• 8.9% discontinued due to adverse events (similar to 8.7% with placebo) 1, 3
• Dosage interruptions: 13%
• Dosage reductions: 6%

Drug Interactions

Avoid Concomitant Use 1:

• Combined P-gp and strong/moderate CYP3A4 inducers (e.g., rifampin, phenytoin, carbamazepine, St. John's wort)

Use with Caution 1:

• Combined P-gp and strong CYP3A4 inhibitors: Monitor more frequently for adverse reactions
• BCRP substrates (e.g., rosuvastatin, sulfasalazine): Avoid when possible; if used, monitor closely and consider dose reduction
• OATP1B1/1B3 substrates (e.g., statins, glyburide): Monitor more frequently; consider dose reduction

Clinical Efficacy Supporting Use

The ARAMIS trial demonstrated compelling benefits 3, 4:

• Median metastasis-free survival: 40.4 months vs 18.4 months with placebo (HR 0.41; P<0.001)
• 3-year overall survival: 83% vs 77% with placebo (HR 0.69; P=0.003)
• Time to symptomatic progression: HR 0.45 (P<0.001)
• Time to pain progression: Significantly delayed

Key Clinical Advantages

Darolutamide demonstrates a favorable safety profile compared to other androgen receptor inhibitors 3, 5:

• No increased risk of falls, fractures, cognitive disorder, or hypertension vs placebo
• Lower seizure risk than enzalutamide or apalutamide
• Maintained quality of life during treatment 6

Common Pitfalls to Avoid

1. Failing to confirm castrate testosterone levels before diagnosing CRPC - always verify testosterone <50 ng/dL 2
2. Not monitoring thyroid function - hypothyroidism is manageable but requires early identification 2
3. Overlooking cardiovascular optimization - ischemic events occurred in 4% of patients 1
4. Using in patients with PSA doubling time >10 months - these patients have indolent disease and may not require immediate treatment 2
5. Forgetting dose adjustments for severe renal or moderate hepatic impairment 1